Get the Stockscreener App
1.95
1.02%
-0.02
Polaryx Therapeutics Inc stock is traded at $1.95, with a volume of 42,572.
It is down -1.02% in the last 24 hours and down -4.65% over the past month.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
See More
Previous Close:
$1.97
Open:
$1.94
24h Volume:
42,572
Relative Volume:
1.25
Market Cap:
$97.20M
Revenue:
Net Income/Loss:
$-6.48M
P/E Ratio:
-14.23
EPS:
-0.137
Net Cash Flow:
$-5.30M
1W Performance:
-2.50%
1M Performance:
-4.65%
6M Performance:
-69.81%
1Y Performance:
+0.00%
1-Day Range:
$1.88
$1.97
1-Week Range:
$1.88
$2.05
52-Week Range:
$1.85
$48.91
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Name
Polaryx Therapeutics Inc
Sector
Industry
Phone
201-940-7236
Address
140 EAST RIDGEWOOD AVENUE, PARAMUS
Compare PLYX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
1.95 | 97.20M | 0 | -6.48M | -5.30M | -0.137 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Initiated | Raymond James | Strong Buy |
| Jul-09-26 | Initiated | H.C. Wainwright | Buy |
| Feb-27-26 | Initiated | Maxim Group | Buy |
Polaryx Therapeutics Inc Stock (PLYX) Latest News
Polaryx Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com India
Polaryx Therapeutics (PLYX) investors back board picks and 2026 auditor - Stock Titan
Polaryx Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com UK
Polaryx Therapeutics (NASDAQ:PLYX) Upgraded to "Hold" at Wall Street Zen - marketbeat.com
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Rating of "Moderate Buy" by Brokerages - marketbeat.com
Polaryx Therapeutics (PLYX) Slips 0.49% to $2.03, Support Holds at $1.93Ease of Movement - vinanet.vn
Polaryx Therapeutics Appoints Will Charlton as Chief Medical Officer Starting September 1, 2026 - Kalkine Media
Polaryx Therapeutics Appoints New Chief Medical Officer - TipRanks
Polaryx Therapeutics Names Will Charlton CMO Ahead of Phase 2 SOTERIA Trial - citybiz
Polaryx appoints Will Charlton as chief medical officer By Investing.com - Investing.com Nigeria
Polaryx appoints Will Charlton as chief medical officer - investing.com
Polaryx raises $10M for phase II rare disease basket trial - BioWorld News
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer - The Manila Times
Polaryx appoints Will Charlton as chief medical officer By Investing.com - Investing.com India
A pediatric doctor with over 15 years’ experience joins Polaryx - Stock Titan
Polaryx appoints Will Charlton as chief medical officer By Investing.com - Investing.com South Africa
Polaryx advances preparations for Phase 2 trial launch in Q4 By Investing.com - Investing.com Nigeria
Polaryx advances preparations for Phase 2 trial launch in Q4 - Investing.com India
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial - The Manila Times
Polaryx plans to test one oral drug across four childhood diseases - Stock Titan
Polaryx (PLYX) Market: Moves 9.66% Lower to $1.87 in the Current Update; the Supplied Trading Band Runs From $1.78 to $1.96 in Latest TradingShort Term Trading Ideas - siam.in
We Think Polaryx Therapeutics (NASDAQ:PLYX) Can Afford To Drive Business Growth - Sahm
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Sahm
Analysts Offer Insights on NA Companies: SpaceX (SPCX) and Polaryx Therapeutics, Inc. (PLYX) - theglobeandmail.com
Polaryx Therapeutics (PLYX) cuts losses as cash rises to $11.5M - Stock Titan
Polaryx Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Raymond James Initiates Polaryx Therapeutics(PLYX.US) With Buy Rating, Announces Target Price $6 - Moomoo
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Polaryx Therapeutics (NASDAQ:PLYX) Coverage Initiated at Raymond James Financial - MarketBeat
PLYX Initiated Coverage by Raymond James -- Strong Buy Rating An - GuruFocus
Raymond James Initiates Polaryx Therapeutics at Strong Buy - marketscreener.com
Raymond James initiates Polaryx Therapeutics stock with strong buy By Investing.com - Investing.com South Africa
Raymond James initiates Polaryx Therapeutics stock with strong buy - Investing.com India
Raymond James initiates Polaryx Therapeutics stock with strong buy By Investing.com - Investing.com Canada
Raymond James initiates Polaryx Therapeutics stock with strong buy - Investing.com Nigeria
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference - 富途牛牛
Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polaryx Therapeutics, Inc. SEC Filing (Jul 28, 2026) - Stock Titan
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Se - GuruFocus
PLYX Initiates Coverage On by Lucid Capital Markets -- Rating Set to Buy - GuruFocus
Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential - Investing.com Canada
PLYX|Polaryx Therapeutics Ord Shs|Price:2.096|Chg%:-0.024 - TradingKey
Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential - Investing.com
Polaryx Therapeutics, Inc. Revenue Breakdown – NASDAQ:PLYX - TradingView
Polaryx Therapeutics Ord Shs (PLYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PLYX|Polaryx Therapeutics Ord Shs|Price:2.090|Chg%:-0.010 - TradingKey
Polaryx Therapeutics, Inc. Revenue Breakdown – BOATS:PLYX - TradingView
Polaryx Therapeutics Announces Chief Medical Officer Resignation - The Globe and Mail
Polaryx Therapeutics (PLYX) Slips 3.45%: Support Level Tested at $2.13Iron Condor Alert - vinanet.vn
Polaryx Therapeutics Inc Stock (PLYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Polaryx Therapeutics Inc Stock (PLYX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Landis G. Michael | Chief Financial Officer |
Feb 18 '26 |
Buy |
2.79 |
2,867 |
7,991 |
228,225 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):